These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2244471)

  • 1. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.
    Heikinheimo O
    Acta Obstet Gynecol Scand; 1990; 69(4):357-8. PubMed ID: 2244471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationships of RU 486.
    Heikinheimo O; Kekkonen R
    Ann Med; 1993 Feb; 25(1):71-6. PubMed ID: 8382070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486.
    Heikinheimo O; Ylikorkala O; Turpeinen U; Lähteenmäki P
    Acta Endocrinol (Copenh); 1990 Sep; 123(3):298-304. PubMed ID: 2239078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mifepristone after low oral doses.
    Kekkonen R; Heikinheimo O; Mandelin E; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):229-34. PubMed ID: 8922876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy.
    Hill NC; Selinger M; Ferguson J; MacKenzie IZ
    Hum Reprod; 1991 Mar; 6(3):458-62. PubMed ID: 1955558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.
    Heikinheimo O
    J Steroid Biochem; 1989 Jan; 32(1A):21-5. PubMed ID: 2913396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review.
    Avrech OM; Golan A; Weinraub Z; Bukovsky I; Caspi E
    Fertil Steril; 1991 Sep; 56(3):385-93. PubMed ID: 1894013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and metabolism of RU 486.
    Lähteenmäki P; Heikinheimo O; Croxatto H; Spitz I; Shoupe D; Birgerson L; Luukkainen T
    J Steroid Biochem; 1987; 27(4-6):859-63. PubMed ID: 3695508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of mifepristone.
    Heikinheimo O
    Clin Pharmacokinet; 1997 Jul; 33(1):7-17. PubMed ID: 9250420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of RU 486 and its active metabolites in humans].
    Földesi I; Falkay G; Kovács L
    Acta Pharm Hung; 1994 Jan; 64(1):17-21. PubMed ID: 8023681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of RU 486 and its demethylated metabolites in humans.
    Heikinheimo O; Haukkamaa M; Lähteenmäki P
    J Clin Endocrinol Metab; 1989 Feb; 68(2):270-5. PubMed ID: 2918046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone.
    Wang JD; Shi WL; Zhang GQ; Bai XM
    Contraception; 1994 Mar; 49(3):245-53. PubMed ID: 8200218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations.
    Hill NC; Selinger M; Ferguson J; MacKenzie IZ
    Br J Obstet Gynaecol; 1990 May; 97(5):406-11. PubMed ID: 2372525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct effects of progesterone and antiprogesterone on human sperm hyperactivated motility and acrosome reaction.
    Uhler ML; Leung A; Chan SY; Wang C
    Fertil Steril; 1992 Dec; 58(6):1191-8. PubMed ID: 1459270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.